Abstract
A decreased central dopaminergic and/or noradrenergic transmission is believed to be involved in the pathophysiology of depression. It is known that dopamine (DA) neurons in the ventral tegmental area (VTA) and norepinephrine (NE) neurons in the locus ceruleus (LC) are autoregulated by somatodendritic D2-like and α2-adrenoceptors, respectively. Complementing these autoreceptor-mediated inhibitory feedbacks, anatomical and functional studies have established a role for noradrenergic inputs in regulating dopaminergic activity, and reciprocally. In the present study, a microiontophoretic approach was used to characterize the postsynaptic catecholamine heteroreceptors involved in such regulations. In the VTA, the application of DA and NE significantly reduced the firing activity of DA neurons. In addition to a role for D2-like receptors in the inhibitory effects of both catecholamines, it was demonstrated that the α2-adrenoceptor antagonist idazoxan dampened the DA- and NE-induced attenuations of DA neuronal activity, indicating that both of these receptors are involved in the responsiveness of VTA DA neurons to catecholamines. In the LC, the effectiveness of iontophoretically applied NE and DA to suppress NE neuronal firing was blocked by idazoxan but not by the D2-like receptor antagonist raclopride, which suggested that only α2-adrenoceptors were involved. In the dorsal hippocampus, a forebrain region having a sparse dopaminergic innervation but receiving a dense noradrenergic input, the suppressant effects of DA and NE on pyramidal neurons were attenuated by idazoxan but not by raclopride. The suppressant effect of DA was prolonged by administration of the selective NE reuptake inhibitor desipramine and, to lesser extent, of the selective DA reuptake inhibitor 1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)-piperazine (GBR12909), suggesting that both the NE and DA transporters were involved in DA uptake in the hippocampus. These findings might help in designing new antidepressant strategies aimed at enhancing DA and NE neurotransmission.
Footnotes
-
This study was supported by the Canadian Institutes for Health Research grant (77838) and salary support from the University of Ottawa Institute of Mental Health Research (to B.P.G. and M.E.), as well as a Canada Research Chair in Psychopharmacology from the Canadian Government, and an Endowed Chair from the University of Ottawa Institute of Mental Health Research (to P.B.).
-
ABBREVIATIONS: DA, dopamine; CA, field of the hippocampus; DAT, dopamine transporter; GBR12909, 1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine; NE, norepinephrine; NET, norepinephrine transporter; LC, locus ceruleus; RT, recovery time; VTA, ventral tegmental area; (+)-3-PP, 3-(3-hydroxyphenyl)-N-n-propylpiperidine.
- Received April 18, 2008.
- Accepted August 14, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|